Lineage Cell Therapeutics (LCTX) Receivables - Other (2016 - 2025)
Historic Receivables - Other for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Q3 2025 value amounting to $549000.0.
- Lineage Cell Therapeutics' Receivables - Other changed N/A to $549000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $549000.0, marking a year-over-year change of. This contributed to the annual value of $581000.0 for FY2022, which is 859.81% up from last year.
- Lineage Cell Therapeutics' Receivables - Other amounted to $549000.0 in Q3 2025.
- Over the past 5 years, Lineage Cell Therapeutics' Receivables - Other peaked at $581000.0 during Q4 2022, and registered a low of $200000.0 during Q2 2022.
- Moreover, its 3-year median value for Receivables - Other was $545000.0 (2022), whereas its average is $482000.0.
- Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Receivables - Other was 859.81% (2022), while the steepest drop was 859.81% (2022).
- Quarter analysis of 3 years shows Lineage Cell Therapeutics' Receivables - Other stood at $535000.0 in 2021, then increased by 8.6% to $581000.0 in 2022, then decreased by 5.51% to $549000.0 in 2025.
- Its last three reported values are $549000.0 in Q3 2025, $581000.0 for Q4 2022, and $545000.0 during Q3 2022.